Preprint Article Version 2 This version is not peer-reviewed

Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain

Version 1 : Received: 19 July 2018 / Approved: 19 July 2018 / Online: 19 July 2018 (06:20:54 CEST)
Version 2 : Received: 18 September 2018 / Approved: 18 September 2018 / Online: 18 September 2018 (06:27:47 CEST)

How to cite: Bee, Y.; Ma, Y.; Chen, J.; Tsai, P.; Sheu, S.; Lin, H.; Huang, H.; Liu, G.; Tai, M. Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain. Preprints 2018, 2018070347 (doi: 10.20944/preprints201807.0347.v2). Bee, Y.; Ma, Y.; Chen, J.; Tsai, P.; Sheu, S.; Lin, H.; Huang, H.; Liu, G.; Tai, M. Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain. Preprints 2018, 2018070347 (doi: 10.20944/preprints201807.0347.v2).

Abstract

Choroidal neovascularization (CNV) is a key pathological feature of several of the leading causes of vision loss including neovascular age-related macular degeneration. Here we show that a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic activities, including tube formation and migration of endothelial cells, and suppressed vascular sprouting from rat aortic ring explants. In rat model of laser-induced CNV, we demonstrate that intravitreal injection of CAD27 significantly attenuated the formation of CNV lesions as measured via fundus fluorescein angiography and choroid flat-mounts (19.5% and 22.4% reductions at 10μg and 20μg of CAD27 injected, respectively). Similarly, the reduction of CNV lesions was observed in the groups of rats that had received topical applications of CAD27 (choroid flat-mounts: 17.9% and 32.5% reductions at 10μg/mL and 20μg/mL of CAD27 installed, respectively). Retinal function was unaffected, as measured using electroretinography in both groups received interareal injection or topical applications of CAD27 at least for 9 days. These findings show that CAD27 can be used as a potential therapeutic alternative for targeting CNV in the diseases such as neovascular age-related macular degeneration.

Subject Areas

choroidal neovascularization; neovascular age-related macular degeneration; calreticulin anti-angiogenic domain

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.